Patient Guide: A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 220 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT06717347
Status: 🟢 Enrolling Now
Condition: Diffuse Large B-Cell Lymphoma
Phase: PHASE3

Where You Can Participate

This study is available at 220 locations across the country.

Top locations include:
  • • Tucson, Arizona
  • • Los Alamitos, California
  • • Los Angeles, California
  • • And 217 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) - Join Clinical Trial NCTNCT06717347

How to Join This Clinical Trial - NCTNCT06717347

Learn how to participate in this PHASE3 trial studying an investigational therapy for Diffuse Large B-Cell Lymphoma. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Diffuse Large B-Cell Lymphoma. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Diffuse Large B-Cell Lymphoma
Treatment Being Tested
Investigational treatment
Study Phase
PHASE3 - Large-scale efficacy study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT06717347 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 220 locations. Find a study site near you:

Clinical Research Site

Tucson, Arizona 85719 - United States

Status: RECRUITING

Clinical Research Site

Los Alamitos, California 90720 - United States

Status: RECRUITING

Clinical Research Site

Los Angeles, California 90048 - United States

Status: RECRUITING

Clinical Research Site

Hialeah, Florida 33013 - United States

Status: RECRUITING

Clinical Research Site

O'Fallon, Illinois 62269 - United States

Status: RECRUITING

Clinical Research Site

Fort Wayne, Indiana 46804 - United States

Status: RECRUITING

Clinical Research Site

Topeka, Kansas 66606 - United States

Status: RECRUITING

Clinical Research Site

Lexington, Kentucky 40536 - United States

Status: RECRUITING

Clinical Research Site

Louisville, Kentucky 40207 - United States

Status: RECRUITING

Clinical Research Site

Grand Rapids, Michigan 49503 - United States

Status: RECRUITING

And 210 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE3 clinical trial for Diffuse Large B-Cell Lymphoma:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships